Gilead Sciences, Inc. (NASDAQ:GILD) Stake Lessened by DeDora Capital Inc.

DeDora Capital Inc. decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 29.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,171 shares of the biopharmaceutical company’s stock after selling 3,002 shares during the period. DeDora Capital Inc.’s holdings in Gilead Sciences were worth $525,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Capital World Investors lifted its holdings in shares of Gilead Sciences by 2.0% in the fourth quarter. Capital World Investors now owns 83,364,123 shares of the biopharmaceutical company’s stock valued at $6,753,350,000 after buying an additional 1,642,736 shares during the period. Capital Research Global Investors lifted its holdings in Gilead Sciences by 3.0% in the 4th quarter. Capital Research Global Investors now owns 59,657,126 shares of the biopharmaceutical company’s stock valued at $4,832,824,000 after acquiring an additional 1,743,418 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Gilead Sciences by 14.4% in the 4th quarter. Wellington Management Group LLP now owns 18,630,134 shares of the biopharmaceutical company’s stock valued at $1,509,227,000 after acquiring an additional 2,350,550 shares during the last quarter. Morgan Stanley boosted its position in shares of Gilead Sciences by 0.9% during the 3rd quarter. Morgan Stanley now owns 16,909,619 shares of the biopharmaceutical company’s stock valued at $1,267,207,000 after purchasing an additional 158,794 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Gilead Sciences in the 4th quarter worth approximately $1,301,624,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Down 0.8 %

NASDAQ:GILD traded down $0.55 during trading hours on Friday, reaching $64.78. The company’s stock had a trading volume of 7,822,720 shares, compared to its average volume of 7,345,331. The company has a market cap of $80.66 billion, a price-to-earnings ratio of 179.94, a price-to-earnings-growth ratio of 1.31 and a beta of 0.22. Gilead Sciences, Inc. has a one year low of $64.33 and a one year high of $87.86. The business’s 50-day moving average is $70.55 and its 200-day moving average is $75.83. The company has a debt-to-equity ratio of 1.08, a current ratio of 0.98 and a quick ratio of 0.72.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. The firm had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. Gilead Sciences’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the prior year, the company posted $1.37 earnings per share. Equities research analysts predict that Gilead Sciences, Inc. will post 3.74 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 4.75%. The ex-dividend date of this dividend is Friday, June 14th. Gilead Sciences’s dividend payout ratio is presently 855.56%.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now directly owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on GILD. Royal Bank of Canada reduced their target price on shares of Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating for the company in a report on Friday, April 26th. TD Cowen decreased their target price on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Friday, April 26th. Morgan Stanley reduced their target price on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a report on Friday, April 26th. Mizuho dropped their price target on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a research note on Thursday, February 22nd. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $105.00 price objective on shares of Gilead Sciences in a research note on Friday, April 19th. Eleven analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $83.69.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.